NCT05119686 - Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

November 17, 2022

Study Completion Date

November 17, 2022

Conditions

GoutArthritis, GoutyHyperuricemiaGout Chronic

Interventions

DRUG

AR882 Dose 1

Solid Oral Capsule

DRUG

AR882 Dose 2

Solid Oral Capsule

DRUG

Placebo

Matching Solid Oral Capsule Placebo

Trial Locations (23)

112

Arthrosi Investigative Site - 301, Taipei

Arthrosi Investigative Site - 304, Taipei

114

Arthrosi Investigative Site, Taipei

333

Arthrosi Investigative Site, Taoyuan District

402

Arthrosi Investigative Site, Taichung

2019

Arthrosi investigative Site, Botany

3124

Arthrosi Investigative Site, Melbourne

16635

Arthrosi Investigative Site, Duncansville

33014

Arthrosi Investigative Site, Miami Lakes

33143

Arthrosi Investigative Site, Miami

33613

Arthrosi Investigative Site, Tampa

44122

Arthrosi Investigative Site, Cleveland

44195

Arthrosi Investigative Site, Cleveland

53217

Arthrosi Investigative Site, Glendale

66212

Arthrosi Investigative Site, Overland Park

75231

Arthrosi Investigative Site, Dallas

77074

Arthrosi Investigative Site, Houston

77375

Arthrosi Investigative Site, Tomball

84088

Arthrosi Investigative Site, West Jordan

85297

Arthrosi Investigative Site, Gilbert

85351

Arthrosi Investigative Site, Sun City

85704

Arthrosi Investigative Site, Tucson

96814

Arthrosi Investigative Site, Honolulu